Key Steps
Step 1: Identify a set of biomarkers of susceptibility from a mixture of biomarkers of susceptibility and biomarkers of response.
Step 2: Develop an imbalanced-data classifier, as the number of susceptible patients is generally much smaller than the number of non-susceptible patients, to identify susceptible patients.
Two step to development of a biomarker classifier for identifying a fraction of susceptible patients: 
Imbalanced Data
Imbalanced data: the class sizes are different substantially.
Ex: clinical diagnostic test of rare diseases, fraud detection. (Much more negative data than positive data)
If P:N has the 1:9 ratio, a procedure predicts all negatives will have 90% accuracy, but 0% sensitivity.
A procedure with a high specificity but very low sensitivity, or vice versa, is not useful in some applications.  Clinical diagnostic tests: high sensitivity.  Epidemiology screening tests: high specificity. 
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Simulation -Summary
 The number of negatives is much larger than the number of positives; it is expected to have high sensitivity and low specificity, and can result in high accuracy in all models.
 Feature selection does not improve the performance of DLDA substantially, compared to the estimates of using all 2000 variables without selection.
 There was little improvement for SVM and RF since the SVM and RF algorithms implicitly performed variable selection; but, many selected variables were not useful for improvement because of imbalanced class sizes.
 The sensitivities of the models developed from B were much higher than the sensitivities developed from S*.
Summary -Pharmacogenomics
 Populations of patients are heterogeneous due to differences in genetic pre-dispositions, lifestyle, or disease characteristics.
 An aim of pharmacogenomics is to identify inter-individual variability with respect to drug or treatment response (both efficacy and toxicity) to guide personalized medicine.
 An initial step to address the population heterogeneity is to assume an existence of a small fraction of susceptible population that can be represented by a set of genomic characteristics -biomarker of susceptibility. As the decision threshold increases, sensitivity decreases and specificity increases. However, the accuracy stays more or less constant.
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